Latest:
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
© 2025 MJH Life Sciences™ and The Center for Biosimilars - Biosimilars, Health Economics & Insights. All rights reserved.
Authors
St John Skilton, PhD
As vice president of product strategy and marketing, St John Skilton manages the new product development at Protein Metrics Inc. With deep domain experience in MS and related analytical tools the biopharmaceutical industry, Skilton has been at the forefront of development for many years.
Latest:
Contributor: The Biosimilars Wave Is Crashing on the Shores of Biopharma Development
St John Skilton, PhD, vice president of product strategy and marketing at Protein Metrics, takes a deep dive into how the development of biosimilars is evolving and how tools, such as mass spectrometry, can help companies keep up with advancing technology.
Amber Skrtic, PharmD
Amber Skrtic, PharmD, CSP, AAHIVP, is Vice President of Trade Relations for CPS Solutions.
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?
Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Pearl Steinzor
Latest:
Dr Ryan Haumschild Draws Link Between Biosimilars, Health Equity in Breast Cancer
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, discusses the growth and continued challenges facing biosimilars used to treat breast cancer.
Susan Trieu, PharmD
Susan Trieu, PharmD, is Senior Vice President of Specialty Clinical Strategy and Trend for CPS Solutions
Latest:
Contributor: Self-Administered Biosimilars Are Coming Quickly—Is Your Clinic Ready?
Four pharmacists offer advice for clinics on how to prepare for new self-administered biosimilar products, including adalimumab biosimilars, and overcome emerging administrative challenges.
Ashling Wahner
Latest:
Denosumab Biosimilars Earn Positive CHMP Opinion for Bone Loss and Giant Cell Tumor of Bone
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the denosumab biosimilars SB16 for all indications referencing Prolia and Xgeva.
Wayne Winegarden, PhD
Wayne Winegarden is a senior fellow and director center for medical economics and innovation at Pacific Research Institute. He received his PhD in economics from George Mason University.
Latest:
Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?
If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.
Elena Wolff-Holz, MD
Global Head Clinical Development, Biocon Biologics
Latest:
Automatic Biosimilar Substitution and Patient Education Advocated by Elena Wolff-Holz, MD
Elena Wolff-Holz, MD, discussed the rationale and safety surrounding the automatic substitution of biosimilars at the pharmacy level, as well as common misconceptions about these medications.
Rosalind Wong, PharmD Candidate
Rosalind Wong is a PharmD candidates at the Daniel K. Inouye College of Pharmacy at the University of Hawai’i at Hilo.
Latest:
Common Patient Questions About Insulin Biosimilars Pertain to Classification
Nuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.
Advertisement
Advertisement